Reported 3 months ago
Pfizer has increased its earnings forecast for 2024 after initially disappointing Wall Street, citing strong sales growth in non-COVID drugs like Eliquis and a better-than-expected second-quarter performance. Despite facing a 98% drop in net income due to restructuring costs, total sales rose 2%, marking the first year-over-year increase since late 2022. Analysts now anticipate adjusted earnings between $2.45 to $2.65 per share, up from earlier estimates.
Source: YAHOO